Actively Recruiting

Age: 20Years - 65Years
All Genders
ID07022704

The Influence of Doxapram on Diaphragmatic Movement in Mechanically Ventilated COPD Patients During Spontaneous Breathing Trial

Led by Cairo University · Updated on 2025-06-26

35

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are studying the effects of doxapram on diaphragmatic movement in patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are undergoing a spontaneous breathing trial while mechanically ventilated. The purpose is to evaluate how doxapram influences breathing muscle function during this trial. This is a prospective observational study sponsored by Cairo University. During the spontaneous breathing trial, all participants will receive doxapram intravenously at a dose of 1.5 mg/kg ten minutes after the trial starts. The movement of the diaphragm will be assessed using respiratory muscle ultrasound by an expert. This treatment and evaluation occur during the breathing trial period. Participants will be monitored before and ten minutes after receiving doxapram for diaphragmatic movement measured in millimeters. Additionally, arterial blood gases and respiratory rate will be recorded at these same times. The study involves observing these outcomes to understand the impact of doxapram on respiratory function during the breathing trial. The study is planned to continue until November 2025.

CONDITIONS

Brief Title

Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial

Who Can Participate

Age: 20Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with moderate to severe chronic obstructive pulmonary disease undergoing spontaneous breathing trial
Not Eligible

You will not qualify if you...

  • Allergy to doxapram
  • Neuromuscular disorders
  • Inability to evaluate the diaphragm
  • Refusal to participate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - During the spontaneous breathing trial session

Participants receive intravenous doxapram during a spontaneous breathing trial while diaphragmatic movement is evaluated by ultrasound.

1 treatment visit (in-person)

Trial Site Locations

Total: 1 location

1

Cairo University

Cairo, Cairo Governorate, Egypt, 6890

Actively Recruiting

Loading map...

Research Team

M

Mina Helmy, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Multicenter, Prospective Trial Evaluating the Safety and E...

Emphysema or COPD

Actively Recruiting

3 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Diaphragmatic excursion: A possible key player for predicting successful weaning in patients with severe COVID-19.

Mina Adolf Helmy, Lydia Magdy Milad, Safinaz Hassan Osman...

https://pubmed.ncbi.nlm.nih.gov/33940248

Doxapram hydrochloride aggravates adrenaline-induced arrhythmias accompanied by bidirectional ventricular tachycardia.

Shota Oikawa, Hiroko Nomura, Miki Nishio...

https://pubmed.ncbi.nlm.nih.gov/24527224

Diaphragmatic Mobility Loss in Subjects With Moderate to Very Severe COPD May Improve After In-Patient Pulmonary Rehabilitation.

Magdalena Rutka, Małgorzata Pałac, Paweł Linek

https://pubmed.ncbi.nlm.nih.gov/33514664